Agios scores its second positive round of data for its lead pipeline drug — but that won't answer the stubborn questions that surround this program
Agios $AGIO bet the farm on its PKR activator drug mitapivat when it recently decided to sell off its pioneering cancer drug Tibsovo and go back to being a development-stage company — for what CEO Jackie Fouse hoped would be a short stretch before they got back into commercialization.
On Tuesday evening, the bellwether biotech flashed more positive topline data — this time from a small group of patients in a single-arm study. And the executive team plans to package this with its earlier positive results from a controlled study to make its case for a quick OK.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 102,300+ biopharma pros reading Endpoints daily — and it's free.